Observational studyDer Urologe. Ausg. A2018
[Phytotherapy in catheter-associated urinary tract infection : Observational study recording the efficacy and safety of a fixed herbal combination containing Tropaeoli majoris herba and Armoraciae rusticanae radix].
Observational study in Der Urologe. Ausg. A, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Clinical evaluation of the efficacy and safety of nasturtium herb and horseradish root versus placebo in the continuous prophylaxis of recurrent uncomplicated cystitis: a double-blind randomised clinical trial.BMC complementary medicine and therapies · 2026Trial
- Modern Solutions to UTIs: The Role of Nanotechnology and Herbal Treatments.Current drug targets · 2025Review
- Non-Antibiotic Prophylaxis for Recurrent UTIs in Neurogenic Lower Urinary Tract Dysfunction (NAPRUN): Study Protocol for a Prospective, Longitudinal Multi-Arm Observational Study.Methods and protocols · 2023Article
- How to Prevent Catheter-Associated Urinary Tract Infections: A Reappraisal of Vico's Theory-Is History Repeating Itself?Journal of clinical medicine · 2022Review
- Catheter-Associated Urinary Tract Infections: Current Challenges and Future Prospects.Research and reports in urology · 2022Review
- [Uncomplicated urinary tract infections : Use of mustard oils].Der Urologe. Ausg. A · 2021Review
- In vitro efficacy of phytotherapeutics suggested for prevention and therapy of urinary tract infections.Infection · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rate of infections occurring during hospitalization is increasing. Urinary tract infections (UTIs) comprise the majority of cases (40%), many of which are catheter-associated. Antibiotic resistance due to antibiotic misuse and overuse exacerbates this situation. Alternative therapies are consequently becoming more important in daily clinical practice. One of the few approved alternatives for the treatment of UTIs is Angocin®, a herbal medicinal product containing nasturtium and horseradish powder.
objectivesEvaluate the efficacy and safety of Angocin® in adult patients with catheter-associated UTIs. MATERIALS AND
methodsNinety-six inpatients with catheter-associated UTI successfully completed a 3-arm, 5-week observational study. Three patient groups were assessed: 1) monotherapy with Angocin® (Repha GmbH, Langenhagen, Germany) (42%), 2) Angocin® as an add-on to antibiotic therapy (29%), and 3) antibiotic therapy alone (29%). Outcome measures included: pathogen number and resistance spectrum in the urine, inflammation markers in the blood, antibiotic use, adverse events (AE), adverse drug reaction (ADR), efficacy, and tolerability.
resultsOne-hundred percent of initial UTIs were healed with add-on therapy and pure antibiotic therapy after an average of 10.5 and 9 days, respectively. The Angocin® monotherapy led to a successful treatment rate of 46% after an average of 28 days. Dosages of Angocin® with 3 × 4 or 3 × 3 tablets per day were markedly below the recommended upper dosage level. The recurrence rate of UTI was markedly reduced with Angocin® mono- and add-on therapies (both 50%) in contrast to pure antibiotic therapy (79.3%). The incidence of AEs and ADRs in the Angocin® monotherapy group (23.8%) was also lower than that reported in the add-on therapy group (44.8%) and pure antibiotic group (34.5%).
conclusionMono- and add-on therapies using the herbal medicinal product Angocin® substantially reduced the recurrence of catheter-associated UTIs in comparison to antibiotic therapy alone. This results in a potential prophylactic efficacy by Angocin® which may represent a promising alternative for the treatment and prevention of recurrent catheter-associated UTIs, reducing antibiotic use. Further clinical trials are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.